RRML - Metabolomic biomarkers of polycystic ovary syndrome related-obesity: a review of the literature

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English

Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12

Advanced search

Top 10 downloaded articles
- February 2024 -
Anti-thyroid peroxidase (TPO) ... 18
Romanian Review of Laboratory ... 14
Recomandarea comună EFLM-COLA... 13
Identification of shared hub g... 12
Challenges in prophylactic the... 10
Approaching Risk Management in... 9
Monocyte to high-density lipop... 8
Understanding the key differen... 7
Understanding the pathogenesis... 7
Atellica CH 930 chemistry anal... 6

Log in

Concept, Design & Programming
Dr. Adrian Man

Nr. 28(3)/2020 DOI:10.2478/rrlm-2020-0017


Metabolomic biomarkers of polycystic ovary syndrome related-obesity: a review of the literature

Camelia Larisa Vonica, Anca Daniela Farcas, Gabriela Roman, Andrada Alina Muresan, Adriana Fodor, Simona Cernea, Carmen Emanuela Georgescu

Correspondence should be addressed to: Adriana Fodor


Background and objectives: Polycystic ovary syndrome (PCOS) displays a phenotype-dependent cardio-metabolic risk. By performing a systematic search of the literature, we aimed to summarize metabolomic signatures associated with obesity in PCOS women. Data sources and study eligibility criteria: We conducted a comprehensive search including: Embase, PubMed, and Web of Science until 31st of May 2019. We used the terms: metabolomics and polycystic ovary syndrome. We excluded the following papers: animal studies, studies that included only lean PCOS women, reviews, meta-analyses, results of interventional studies, those that did not apply metabolomic techniques. Results: The lipid signature in obese women with PCOS showed increased levels of free fatty acids (carnitine, adipic acid, linoleic acid, oleic acid) and lower levels of lysophosphatidylcholines and glycerolphosphocholine compared with non-obese PCOS women. Regarding carbohydrate metabolism, a decrease in citric and lactic acid levels characterized obese PCOS women. Decreased lactic acid in obese PCOS women suggests augmented insulin stimulated glucose muscle use in lean, but not in obese women. Considering amino acid metabolomic markers, valine, glycine, serine, threonine, isoleucine and lysine were higher in obese PCOS women. Patients with visceral obesity presented a diminished uptake of essential amino acids, BCAA, leucine and serine in the skeletal muscle. α-ketoglutarate was significantly higher in obese women with PCOS in comparison with lean women with PCOS, distinguishing these 2 subgroups of PCOS with high ‘predictive accuracy’. Limitations: Overall, a small number of studies have focused on the impact of obesity on the metabolic fingerprints of PCOS women. There is need for properly controlled, high-quality studies. Conclusions: There is compelling evidence of significant alterations in carbohydrate, lipid, and amino acid metabolism in women with PCOS and obesity. Metabolomics may identify new metabolic pathways involved in PCOS and improve our understanding of the complex relation between PCOS and obesity in order to personalize PCOS therapy.

Keywords: untargeted metabolomics, polycystic ovary syndrome, obesity, biomarkers, targeted metabolomics

Received: 9.12.2019
Accepted: 13.2.2020
Published: 24.2.2020

  PDF Download full text PDF
(697 KB)
How to cite
Vonica CL, Farcas AD, Roman G, Muresan AA, Fodor A, Cernea S, et al. Metabolomic biomarkers of polycystic ovary syndrome related-obesity: a review of the literature. Rev Romana Med Lab. 2020;28(3):241-55. DOI:10.2478/rrlm-2020-0017